Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.

Slides:

Advertisements

Similar presentations

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections.

Advertisements

What's New in Basal Insulin for Diabetes

Where Are We on the Path to Elimination of Chronic Hepatitis C?

Short-, Intermediate-, Long-Acting Insulins

Diabetic Dyslipidemia in Practice

Applying Data to Practice

Special Consideration in Insulin Therapy

Program Goals. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding.

An Update on Oral Prostanoids: Advancing Care for PAH?

SGLT2 Inhibitors: What Do the Data Mean for My Patients?

New Patient-Friendly Options for Managing Insulin Dosing

Modern Strategies for Basal Insulin Use in T2D

Insulin Innovation.

Insulin/GLP-1 Agonist Combinations

Program Goals. Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin.

Clinical Advances in Type 2 Diabetes and Cardiovascular Risk

How Early Should Basal Insulin Be Used in T2D Management?

Optimizing Outcomes in the Management of GIST

Examining CV Effects of Basal Insulin Therapy

What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?

Innovative Insulin Combinations: A New strategy for the Person With T2DM.

Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?

Tailoring Hemophilia Prophylaxis Therapy

Emerging Basal Insulins for Diabetes

Insights into Insulin Treatment Challenges: Real-World Evidence and Clinical Trial Data.

GLP-1 Receptor Agonists: How Early Is Appropriate?

Statins and New-Onset Diabetes REAL Updates and Clinical Implications

Talking to Patients About Diabetes Management

The future of urate-lowering strategies for gout

Novel Insulin Combinations: What Does the Primary Care Physician Need to Know?

Integrated Diabetes Care: How Can We Make the Best Use of New Technology?

Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.

Insulin/GLP-1 Agonist Combinations

Insulin Use in Primary Care: Practice Challenges

Insulin Innovation.

The Importance of Getting the Dose Right in HF

New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.

Predictive Low Glucose Suspend (PLGS)

The Primary Care Guide to New CGM Devices and the AGP

Novel Approaches to T1D Management

Management of Systematic Lupus Erythematosus

T2DM Management.

Better Diabetes Control With Novel Basal Insulins

Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?

When Is Intrathecal Drug Delivery Appropriate?

Program. Basal Insulin in the Modern Era The CDE's Role in Improving Utilization and Outcomes.

Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.

Dual SGLT1/SGLT2 Inhibition in T1D

Insulin Innovation.

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.

Statins, Obesity, and Hyperlipidemia

Oral Prostacyclin Pathway Agents in PAH

COMBINATIONS AND COFORMULATIONS: THE FUTURE OF INSULIN THERAPY?

Glucose Management and Statin Therapy

Add-On Therapy to Insulin in T1DM Management

Incorporating Prostacyclins Into Practice

Challenges in LA SCCHN.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

When Is Intrathecal Drug Delivery Appropriate?

2015 EASD In Review: CV Risk management in t2dm

Glucose Management and Statin Therapy

Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.

Fixed-Ratio Combination Therapy in T2DM

Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.

Emerging Basal Insulins for Diabetes

Fresh perspectives ON BASAL Insulins in diabetes care

The Power of As-Treated Analyses

The Challenge of Insulin Titration

Presentation transcript:

Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data

Program Overview

Delays in Starting Insulin Therapy

Clinical Inertia: A Hurdle in Insulin Therapy

Initiation of Insulin Therapy Is Often Delayed

Initiation of Insulin Therapy Is Often Delayed (cont)

Integrated Diabetes Care: Chronic Disease Model

Patient Support Programs

Improving Insulin Initiation and Intensification

The Role of Technology

Patient-Led Insulin Titration

Daily Insulin Dose Adjustment: Canadian Titration Study

Benefits of Patient Education

Group Insulin Initiation

What Is Real-World Trial Data?

Real-World Data on Basal Insulins

Real-World Trials Underway

Available Real-World Data on Basal Insulins

Available Real-World Data on Basal Insulins (cont)

Intensification Options for Minimizing Weight Gain and Hypoglycemia

T2DM Management in Primary Care

Summary

Abbreviations

Abbreviations (cont)